Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2463MR)

This product GTTS-WQ2463MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000885.6; NM_000889.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695
UniProt ID P13612; P26010
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2463MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14540MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ5848MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ6758MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS-1062
GTTS-WQ3531MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ14605MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SC0001
GTTS-WQ9226MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ15617MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ8702MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW